3 mIU/mL患者數(shù)為8例,明顯高于對照組的4例,兩組比較差異有統(tǒng)計學(xué)意義(P<0.05);觀察組血HCG最高滴定值>105 mIU/mL患者數(shù)為6例,明顯低于對照組的18例,兩組比較差異有統(tǒng)計學(xué)意義(P<0.05)。兩組患者不同程度出現(xiàn)白細(xì)胞減少、惡心、嘔吐、口腔潰瘍等不良反應(yīng),但組間差異無統(tǒng)計學(xué)意義。結(jié)論 5-Fu聯(lián)合甲氨蝶呤治療惡性滋養(yǎng)細(xì)胞腫瘤療效確切且安全可靠,值得臨床推廣應(yīng)用。;Objective To investigate the clinical efficacy of 5-fluorouracil (5-Fu) combined with methotrexate in the treatment of malignant trophoblastic tumor. Methods Taking admission number as number, according to the random number table, 80 patients diagnosed as malignant tumor were randomly divided into two groups, 40 cases in each group. Patients in control group were treated with 5-Fu chemotherapy; Patients in observation group were treated with 5-Fu combined with methotrexate. The changes of blood HCG, clinical symptoms, efficacy, and adverse reactions of two groups of patients after treatment were observed. Results After treatment, the clinical effective rate of observation group (97.5%) was significantly higher than that in the control group (85%) (P<0.05). After treatment, the number of patients with the highest HCG value of blood less than 103 mIU/mL in observation group (8 cases) were significantly higher than the control group (4 cases) (P<0.05); The number of patients with the highest HCG value of blood more than 105 mIU/mL in the observation group (6 cases) was significantly lower than that in the control group (18 cases) (P<0.05). There were different degree of adverse reactions in patients with leukopenia, nausea, vomiting, oral ulcer, but no significant difference between the groups. Conclusion 5-Fu combined with methotrexate is effective and safe in the treatment of malignant tumor. It is worthy of clinical application."/>

醉酒后少妇被疯狂内射视频,一本色道久久综合一,在线天堂新版资源www在线下载,中文字幕乱人伦高清视频,中字幕视频在线永久在线观看免费

首頁 > 過刊瀏覽>2016年第39卷第3期 >2016,39(3):425-428. DOI:10.7501/j.issn.1674-6376.2016.03.019
上一篇 | 下一篇

5-氟尿嘧啶聯(lián)合甲氨蝶呤治療惡性滋養(yǎng)細(xì)胞腫瘤的臨床療效

Clinical analysis on 5-fluorouracil combined with methotrexate in treatment of malignant trophoblastic tumor

發(fā)布日期:2016-05-27
您是第位訪問者
藥物評價研究 ® 2025 版權(quán)所有
技術(shù)支持:北京勤云科技發(fā)展有限公司
津備案:津ICP備13000267號 互聯(lián)網(wǎng)藥品信息服務(wù)資格證書編號:(津)-非經(jīng)營性-2015-0031